CD30

Tumor necrosis factor receptor superfamily, member 8
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1D01
Identifiers
Symbols	TNFRSF8 ; CD30; D1S166E; Ki-1
External IDs	OMIM: 153243 MGI: 99908 HomoloGene: 949 GeneCards: TNFRSF8 Gene
Gene ontology Molecular function • transmembrane signaling receptor activity Cellular component • cytoplasm • plasma membrane • integral component of membrane • extracellular exosome Biological process • signal transduction • negative regulation of cell proliferation • positive regulation of tumor necrosis factor biosynthetic process • positive regulation of apoptotic process • positive regulation of TRAIL biosynthetic process • cellular response to mechanical stimulus Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	943	21941
Ensembl	ENSG00000120949	ENSMUSG00000028602
UniProt	P28908	Q60846
RefSeq (mRNA)	NM_001243	NM_009401
RefSeq (protein)	NP_001234	NP_033427
Location (UCSC)	Chr 1: 12.06 – 12.14 Mb	Chr 4: 145.27 – 145.32 Mb
PubMed search	[1]	[2]

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.

Cancer treatment

CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:

1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen

Interactions

CD30 has been shown to interact with TRAF5, TRAF1, TRAF2 and TRAF3.

External links

• CD30 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.